The IU and Purdue Analytical Proteomics Team was awarded a grant of about $7 million as one of five national centers selected by the NCI for its clinical proteomic technologies initiative for cancer, a five-year, $104 million national program. The five grants, totaling $35.5 million, will establish a collaborative network to assess the proteomics technologies used to improve cancer research and treatment.
Proteomics is the study of proteins: their structure, function and how they interact with each other. The goal of the NCI initiative is to enable cancer researchers to make use of standardized proteomics methodologies to discover proteins and protein components -- biomarkers -- that are relevant to cancer.
Indiana is well known for having experts in proteomics at Purdue, IU-Bloomington and the IU School of Medicine in Indianapolis, as well as private industry. The Analytical Proteomics Team grant will pair those proteomics experts with cancer researchers and clinicians at the IU School of Medicine and experts in statistical and computer analysis at IU's School of Informatics.
Fred Regnier, Ph.D., Purdue's John H. Law Distinguished Professor of Chemistry, will be principal investigator for the team.
"This is a perfect example of how great things will happen in Indiana when IU, Purdue and the private sector collaborate on life sciences research," said D. Craig Brater, M.D., vice president of IU with responsibility for life sciences and dean of the IU School of Medicine.
Four hundred clinical samples will be collected for breast cancer analysis by the Hoosier Oncology Group, an Indiana statewide network of cancer physicia
'"/>
Contact: Eric Schoch
eschoch@iupui.edu
317-274-7722
Indiana University
28-Sep-2006